| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4690 | Trichomonacid | Novel inhibitor of Mycobacterium marinum MelF (Rv1936), exhibiting bacteriostatic/bactericidal activity against M. marinum and M. tuberculosis in vitro |
|
| DCC4691 | Seviteronel | Novel potent CYP17 lyase inhibitor, inhibiting androgen production without mineralocorticoid excess or cortisol depletion |
|
| DCC4692 | sew05920 | Novel telomerase inhibitor |
|
| DCC4693 | Sew-05929 | The First potent SecA inhibitor |
|
| DCC4694 | Sf-1-087 | Potent and selective STAT5 inhibitor |
|
| DCC4695 | Sf-22 (npy Y2 Antagonist) | Potent, selective, and highly brain-penetrant NPY Y2 receptor antagonist |
|
| DCC4696 | Sf2535 | Novel dual inhibitor of BRD4 and PI3K, inhibiting BRD4, PI3Kα, PI3Kδ, and PI3Kγ with IC 50 values of 277, 714, 27, and 1170 nM, respectively |
|
| DCC4697 | Sfom-0046 | Novel anticancer agent, arresting cell cycle in S-phase and causes DNA replication stress leading to the phosphorylation of H2AX into gamma-H2AX |
|
| DCC4698 | Sfrp-1 Inhibitor-1 | Cell-permeable antagonist of secreted frizzled related protein-1(sFRP-1), inhibiting Wnt-3/frizzled interaction and restoring cellular response to Wnt-3 stimulation |
|
| DCC4699 | Sfti-1 | Highly Potent and Selective Plasmin Inhibitor, Attenuating Fibrinolysis in Plasma |
|
| DCC4700 | Sgc-camkk2-1 | Novel probe for CAMKK2/CAMKK1 |
|
| DCC4701 | Sgc-clk-1 | Novel probe for CLK1, CLK2, and CLK4 |
|
| DCC4702 | Sgc-gak-1n | Negative control for SGC-GAK-1 (GLXC-31266) |
|
| DCC4703 | Sge201 | Novel potent allosteric modulator of N-methyl-D-aspartate receptors (NMDAR) |
|
| DCC4704 | Sgi-10067 | PKM2 activator, potently inhibiting proliferation of cancer cells in media lacking serine |
|
| DCC4705 | Sgi-9380 | PKM2 activator, potently inhibiting proliferation of cancer cells in media lacking serine |
|
| DCC4706 | Sgk1 Inhibitor 17a | Novel highly selective SGK1 inhibitor with a highly optimized profile suitable for oral dosing as a potentially disease-modifying agent for osteoarthritis |
|
| DCC4707 | Sglt1/2-in-8 | Novel Potent SGLT1/2 Dual Inhibitor |
|
| DCC4708 | Sgx393 | Novel inhibitor of the CML mutant Bcr-AblT315I, preempting in vitro resistance when combined with nilotinib or dasatinib. |
|
| DCC4709 | Sh-053-r-ch3-2’f | Selective agonist of GABA A receptors α5 subunit |
|
| DCC4710 | Sh-053-s-ch3-2'f | Potent and selective agonist of GABAA receptors α5 subunit |
|
| DCC4711 | Sh-11037 | Novel potent sEH inhibitor, effectively blocking key angiogenic properties of human retinal endothelial cells (HRECs), inhibiting choroidal sprouting and significantly suppressing CNV lesion volume |
|
| DCC4712 | Sh-11052 | Novel inhibitor of endothelial cell growth |
|
| DCC4713 | Sh-2251 | Novel selective inhibitor of the generation of IL-5-producing Th2 cells and induction of active histone modifications at the IL5 gene locus during Th2 cell differentiation |
|
| DCC4714 | Sha 14-1 | Stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypassing drug resistances and synergizing cancer therapies in human leukemia cell |
|
| DCC4715 | She-196 | First in Class Hypoglycemic Agent with Extra-Strong Action, increasing insulin sensitivity, improving glucose tolerance, reducing fasted insulin level and insulin sensitivity, decreasing total body and interscapular fat mass and also increasing the activi |
|
| DCC4716 | Sherpa Bmi-135 | Novel Selective Human ER Partial Agonist (ShERPA) |
|
| DCC4717 | Sheta2 | Selective inhibitor of cancer cell growth, exerting chemoprevention activity without evidence of toxicity |
|
| DCC4718 | Sh-i-14 | Novel Inhibitor of Phospho-STAT3 Through Induction of Protein Tyrosine Phosphatase PTPN6 |
|
| DCC4719 | Shield-2 | Novel potent stabilizing ligand for FKBP-derived destabilizing domains |
|
